logo
Humans Are Evolving Right in Front of Our Eyes on The Tibetan Plateau

Humans Are Evolving Right in Front of Our Eyes on The Tibetan Plateau

Yahoo22-05-2025

Humans are not yet done cooking. We're continuing to evolve and adjust to the world around us, the records of our adaptations written in our bodies.
We know that there are some environments that can make us unwell. Mountain climbers often succumb to altitude sickness – the body's reaction to a significant drop in atmospheric pressure, which means less oxygen is taken in with each breath.
And yet, in high altitudes on the Tibetan Plateau, where oxygen levels in the air people breathe are notably lower than lower altitudes, human communities thrive.
In the more than 10,000 years the region has been settled, the bodies of those living there have changed in ways that allow the inhabitants to make the most of an atmosphere that for most humans would result in not enough oxygen being delivered via blood cells to the body's tissues, a condition known as hypoxia.
"Adaptation to high-altitude hypoxia is fascinating because the stress is severe, experienced equally by everyone at a given altitude, and quantifiable," anthropologist Cynthia Beall of Case Western Reserve University in the US told ScienceAlert.
"It is a beautiful example of how and why our species has so much biological variation."
Beall has been studying the human response to hypoxic living conditions for years. In research published in October 2024, she and her team unveiled some of the specific adaptations in Tibetan communities: traits that help the blood deliver oxygen.
To unlock this discovery, the researchers delved into one of the markers of what we call evolutionary fitness: reproductive success. Women who deliver live babies are those who pass on their traits to the next generation.
The traits that maximize an individual's success in a given environment are most likely to be found in women who are able to survive the stresses of pregnancy and childbirth.
These women are more likely to give birth to more babies; and those babies, having inherited survivability traits from their mothers, are also more likely to survive to adulthood, and pass the traits on to the next generation.
That's natural selection at work, and it can be a bit strange and counterintuitive; in places where malaria is common, for example, the incidence of sickle cell anemia is high, because it involves a gene that protects against malaria.
Beall and her team made a study of 417 women between the ages of 46 and 86 years who have lived all their lives in Nepal above altitudes of around 3,500 meters (11,480 feet). The researchers recorded the number of live births, ranging between 0 and 14 per woman for an average of 5.2, as well as health and physical information and measurements.
Among the things they measured were levels of hemoglobin, the protein in red blood cells responsible for delivering oxygen to tissues. They also measured how much oxygen was being carried by the hemoglobin. Interestingly, the women who demonstrated the highest rate of live births had hemoglobin levels that were neither high nor low, but average for the testing group.
But the oxygen saturation of the hemoglobin was high. Together, the results suggest that the adaptations are able to maximize oxygen delivery to cells and tissues without thickening the blood – a result that would place more stress on the heart as it struggles to pump a higher viscosity fluid more resistant to flow.
"Previously we knew that lower hemoglobin was beneficial, now we understand that an intermediate value has the highest benefit. We knew that higher oxygen saturation of hemoglobin was beneficial, now we understand that the higher the saturation the more beneficial. The number of live births quantifies the benefits," Beall said.
"It was unexpected to find that women can have many live births with low values of some oxygen transport traits if they have favorable values of other oxygen transport traits."
The women with the highest reproductive success rate also had a high rate of blood flow into the lungs, and their hearts had wider than average left ventricles, the chamber of the heart responsible for pumping oxygenated blood into the body.
Taken all together, these traits increase the rate of oxygen transport and delivery, enabling the human body to make the most of the low oxygen in the air respired.
It's important to note that cultural factors can play a role, too. Women who start reproducing young and have long marriages seem to have a longer exposure to the possibility of pregnancy, which also increases the number of live births, the researchers found.
Even taking that into account, however, the physical traits played a role. Nepalese women with physiologies most similar to women in unstressed, low altitude environments tended to have the highest rate of reproductive success.
"This is a case of ongoing natural selection," Beall said. "Understanding how populations like these adapt gives us a better grasp of the processes of human evolution."
The research was published in the Proceedings of the National Academy of Sciences.
An earlier version of this article was published in October 2024.
Nanoplastics Stick to Toxic Bacteria, Forming a Deadly Combination
Expert Explains FDA's New COVID Vaccine Rules in The US
Your Perfume Could Be Messing With Your Chemical Force Shield

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Year-Long Methotrexate Not Helpful for Inflammatory Knee OA
Year-Long Methotrexate Not Helpful for Inflammatory Knee OA

Medscape

time9 hours ago

  • Medscape

Year-Long Methotrexate Not Helpful for Inflammatory Knee OA

Compared with placebo, low-dose methotrexate administered weekly at doses up to 15 mg for 52 weeks did not relieve knee pain or reduce the size of effusion-synovitis in patients with inflammatory knee osteoarthritis (OA). METHODOLOGY: Researchers in China conducted a multicenter, clinical trial between July 2019 and January 2023 to examine whether low-dose methotrexate can reduce knee pain and effusion-synovitis in knee OA. They included 215 patients (mean age, 60.6 years; 89% women) with inflammatory knee OA and effusion-synovitis who were randomly assigned to receive either methotrexate or placebo, with weekly 5 mg folic acid supplementation given 1 day after treatment. Participants continued their regular medications (except corticosteroids and anti-synovitis drugs), did not take trimethoprim, and avoided alcohol during the trial. Primary outcomes were changes in knee pain on the visual analog scale (VAS) and inflammation measured by the effusion-synovitis maximal area on MRI over 52 weeks. Secondary outcomes were assessment of pain, stiffness, and physical function; changes in infrapatellar fat pad signal intensity; and evaluation of response to the assigned treatment. TAKEAWAY: At week 52, no significant difference was found between methotrexate and placebo groups in terms of VAS pain and effusion-synovitis maximal area (between-group difference, 0.3 mm; 95% CI, -6.7 to 7.3 mm and 0.1 cm 2 ; 95% CI, -0.8 to 1.0 cm 2 , respectively). ; 95% CI, -0.8 to 1.0 cm , respectively). No significant differences were observed between the two groups in terms of any of the prespecified secondary outcomes. The frequency of experiencing at least one adverse event was comparable between the methotrexate and placebo groups (29.6% and 24.3%, respectively); however, elevated concentrations of liver enzymes were more common in the methotrexate group. IN PRACTICE: 'Given the lack of efficacy of MTX [methotrexate] across knee OA studies and the known potential adverse events, it is not recommended for the treatment of painful, inflammatory knee OA. We now need to focus our attention on treatments that can both inhibit joint inflammation and stimulate chondrocytes within the cartilage to synthesize replacement matrix. The future of pharmaceuticals for knee OA needs to move past MTX,' Nancy E. Lane, MD, UC Davis Health, Sacramento, California, wrote in an accompanying editorial. SOURCE: This study was led by Zhaohua Zhu, PhD, Zhujiang Hospital, Southern Medical University, Guangzhou, China. It was published online on June 2, 2025, in JAMA Internal Medicine . LIMITATIONS: This study was conducted during COVID-19 shutdowns, which delayed recruitment and potentially increased loss to follow-up and nonadherence rates. The findings may not be fully generalizable because most participants were women, and racial and ethnic diversity was limited. The relatively small number of participants in each subgroup may have limited the ability to detect significant benefits in specific populations. DISCLOSURES: This study received funding from the National Key Research and Development Program of China, the National Natural Science Foundation of China, and the Clinical Research Startup Program of Southern Medical University. One author reported providing consulting advice on scientific advisory boards for various pharmaceutical companies outside the submitted work.

PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China
PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China

Associated Press

time10 hours ago

  • Associated Press

PanBrain Technology, with EEG and tDCS Technologies, Wins Dual Honors in China

PanBrain Technology has been awarded as 'National High-tech Enterprise' and 'Specialized, Refined, Distinctive and Innovative' SME in Shenzhen 'Quality First, Technology Priority, Continuous Evolution, and User-Centric Innovation'— PanBrain Technology CA, UNITED STATES, June 6, 2025 / / -- PanBrain Technology Co., Ltd., a leading innovator in brain health technology, has been awarded the 2024 'National High-tech Enterprise' certification along with the 'Specialized, Refined, Distinctive and Innovative' Small and Medium Enterprise (SME) title in Shenzhen. These honors highlight the company's groundbreaking work in non-invasive brain-computer interface (BCI) technologies and strengthen its position in the global market. Driving Innovation in Non-Invasive Brain-Computer Interfaces Founded to revolutionize brain health, PanBrain Technology has dedicated itself to the development of advanced non-invasive BCI solutions. Its flagship product, the PanBrain Energy Capsule, combines sophisticated EEG monitoring with transcranial direct current stimulation (tDCS) to enhance cognitive performance, emotional regulation, and neuroplasticity. By targeting the prefrontal cortex, the device aims to restore neurotransmitter balance, thereby improving fluid intelligence and overall cognitive function. Recognition of Technological Excellence and Commercial Success The 'National High-tech Enterprise' certification underscores PanBrain Technology's robust research and development capabilities and successful commercialization of its innovations. This prestigious designation places the company among China's foremost technology enterprises, recognized for advancing scientific and technological frontiers. Commitment to Specialized Market Needs and Social Impact PanBrain Technology's distinction as a 'Specialized, Refined, Distinctive and Innovative' SME reflects its strategic focus on serving specific user groups, including the elderly, individuals with mood disorders, and those suffering from insomnia and anxiety. The company's tailored solutions, supported by rigorous scientific research, address these societal health challenges with user-friendly designs and innovative technology. Industry Recognition and Competition Success The PanBrain Energy Capsule has earned praise from users, healthcare professionals, and industry experts alike. The product was a finalist and received an Excellence Award at the 2024 China Shenzhen Innovation and Entrepreneurship Competition. Furthermore, PanBrain Technology was selected to represent Shenzhen in the finals of the 13th National Innovation and Entrepreneurship Competition, scheduled for Hangzhou in Q4 2024. Looking to the Future: Expanding Global Impact Committed to ongoing innovation, PanBrain Technology plans to advance its BCI technologies further, expand its product portfolio, and grow its global presence. The company continues to uphold its core values of 'Quality First, Technology Priority, Continuous Evolution, and User-Centric Innovation' as it strives to improve cognitive health and mental well-being worldwide. Panbrain PanBrain Technology [email protected] Visit us on social media: Facebook X LinkedIn Instagram YouTube Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

This common prescription drug could reduce deaths by sepsis, study finds
This common prescription drug could reduce deaths by sepsis, study finds

Yahoo

time10 hours ago

  • Yahoo

This common prescription drug could reduce deaths by sepsis, study finds

Critically ill patients with sepsis who are given statins may be more likely to survive, new research suggests. Researchers set out to explore whether the cholesterol-busting drugs may bring additional benefits for patients. The new study examined information on sepsis patients who received statins during a stint in intensive care and compared it with patients in a similar situation who did not receive statins. Some 14.3 per cent of 6,000 sepsis patients who were given statins died within 28 days. This is compared with 23.4 per cent of 6,000 patients who did not receive statin therapy. The research team from China said that this equates to a 39 per cent reduced risk of death within a month. The research, based on data from thousands of patients at a hospital in Israel between 2008 and 2019, also found that 7.4 per cent of statin patients died while in the intensive care unit compared with 13.6 per cent of those who did not receive statins. And during their overall hospital stay, some 11.5 per cent of sepsis patients who were given statins died, compared with 19.1 per cent of sepsis patients who did not take statins. However, it appeared that those who were not prescribed statins had a slightly shorter hospital stay compared with those who did receive them – an average of eight days compared with almost 10 days. 'We found that statin users exhibited decreased 28-day all-cause mortality,' the authors wrote in the journal Frontiers in Immunology. Sepsis is a life-threatening reaction to an infection that occurs when the immune system overreacts and starts to damage the body's tissues and organs. In the UK, 245,000 people are affected by sepsis every year. UK sepsis experts said that 'anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored' as they called for larger trials to confirm the findings. Statins are known as cholesterol-busting drugs because they can help lower the level of low-density lipoprotein (LDL) cholesterol in the blood. But experts said that they also have other benefits, including reducing inflammation and antibacterial effects. The research team called for larger trials to confirm their findings. 'Our large, matched cohort study found that treatment with statins was associated with a 39 per cent lower death rate for critically ill patients with sepsis, when measured over 28 days after hospital admission,' said Dr Caifeng Li, the study's corresponding author and an associate professor at Tianjin Medical University General Hospital in China. 'These results strongly suggest that statins may provide a protective effect and improve clinical outcomes for patients with sepsis.' Commenting on the study, Dr Ron Daniels, founder and chief executive of the UK Sepsis Trust, said: 'It has been known for some time that the anti-inflammatory properties of statins confer a survival benefit on those who take them if they develop sepsis. 'Whilst previous studies have failed to show a similar survival benefit in treating people with sepsis with statins, this new study supports calls for a large, multi-country, randomised control trial. 'Anything which might reduce the burden of a condition which claims one in five lives worldwide needs to be rigorously explored.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store